



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

April 12, 2021



Daily Change in COVID-19 Cases, US

January 22, 2020 – April 10, 2021

TOTAL Cases Reported Since 1/22/20

30,965,577

NEW Cases Reported to CDC on 4/10/21

68,012

Change in 7-Day Case Average

+3.3%


Current 7-Day Case Average (4/4/21 - 4/10/21)

66,570

Prior 7-Day Case Average (3/28/21 - 4/3/21)

64,449

Peaks in New Cases and Highest 7-Day Moving Average		
	Highest Daily Number of New Cases	Highest 7-Day Moving Average
Current	314,861 (1/8/21)	249,697 (1/8/21)
2nd Peak	75,624 (7/17/20)	67,358 (7/21/20)
1st Peak	42,560 (4/6/20)	31,942 (4/12/20)



*7-day averages exclude historical cases reported retroactively by states



New Admissions of Patients with Confirmed COVID-19

August 1, 2020 – April 9, 2021

Patients Currently Hospitalized with COVID on 4/9/21

33,919

New Admissions on 4/9/21

5,278

Peak in New Admissions (1/5/21)

17,988

Change in 7-Day Average of New Admissions


+6.6%

Current 7-Day Average of New Admissions (4/3/21 - 4/9/21)

5,369

Prior 7-Day Average of New Admissions (3/27/21 - 4/2/21)

5,036



Daily Change in COVID-19 Deaths, United States

January 22, 2020 – April 10, 2021

TOTAL Deaths Reported Since 1/22/2020

558,843

NEW Deaths Reported to CDC on 4/10/21

750

Change in 7-Day Death Average

-5.2%

Current 7-Day Death Average (4/4/21 - 4/10/21)


684

Prior 7-Day Death Average (3/28/21 - 4/3/21)

721

Forecasted Total Deaths by 5/1/21

568,000 to 588,000



● New Deaths — 7-Day Moving Average - New Deaths*

*7-day averages exclude historical cases reported retroactively by states





Search

[Advanced Search](#)

Health Equity

Minority Health and Health Equity



Racism and Health




<https://www.cdc.gov/healthequity/racism-disparities/index.html>





WEAR A MASK



STAY 6 FEET APART



AVOID CROWDS



AVOID TRAVEL

“Breakthrough” Infections (Vaccine Failure) – Background

- Breakthrough infection/vaccine failure: when a person contracts an infection despite being vaccinated against it
- Seen with all vaccines, in clinical trials and in the real world – **no vaccine is 100% efficacious/effective**
- Primary vaccine failure: the body does not mount an adequate response to vaccine because of
 - Immune status, health status, age, genetics, immunosuppressive medications
 - Imperfect vaccine composition, storage or delivery
- Secondary vaccine failure may occur when immunity fades over time
- A vaccine also may fail if a person is exposed to new/different strain or variant of pathogen – e.g. influenza virus, which mutates rapidly and “drifts” genetically
- **However, even if a vaccine fails to completely protect against infection, it often protects against serious disease**



Effectiveness of Selected Vaccines

	Effectiveness	Recommended Doses
Influenza	40-60%	1
Chickenpox	92%	2
Measles	97%	2
Polio	99%	3-4
Mumps	88%	2
Shingles	90%	2

Sources: CDC; *Plotkin's Vaccines*, 7th edition, 2017.



Benefits of the Flu Vaccine and the Importance of Partial Protection

- **If you are vaccinated, you are less likely to get the flu.**
- **Even if you do get sick, vaccination can reduce the severity and duration of illness and can help keep you out of the hospital.**



The Benefits of Flu Vaccination, Despite Modest (39%) Vaccine Effectiveness, 2019-2020 Season

- About 51.8% of people six months and older in the United States were vaccinated during the 2019-2020 flu season
- CDC estimates that flu vaccine prevented
 - 7.5 million flu illnesses
 - 3.7 million flu-associated medical visits
 - 105,000 flu hospitalizations
 - 6,300 flu deaths



Number of COVID-19 Cases in Phase 3 Clinical Trials of EUA Vaccines

Vaccine	Vaccine group	Placebo group	Reference
Moderna	11/14,134	185/14,073	<i>N Engl J Med</i> 2021; 384:403
Pfizer/BioNTech	8/21,720	162/21,728	<i>N Engl J Med</i> 2020; 383:2603
Johnson & Johnson	117/19,514	351/19,544	www.fda.gov/media/146217/download Table 15



COVID-19 Cases in U.S. Studies of “Real-World” Effectiveness

	Fully vaccinated people	Unvaccinated people	Reference
U.S. general adult population, Mayo Clinic system (Arizona, Florida, Minnesota, Wisconsin)	4/8,041	35/8,046	C Pawlowski et al. <i>medRxiv</i> , 2/18/2021
U.S. healthcare personnel, first responders, and other essential and frontline workers	3/2,479	161/895	MG Thompson et al. <i>MMWR</i> 2021;70:495
U.S. healthcare workers (California)	7/4,167	145/5,794 (days 1-7 after 1 dose)	J Keehner et al. <i>NEJM</i> , 3/23/2021
U.S. healthcare workers (Texas)	4/8,121	234/8,969	W Daniel et al. <i>NEJM</i> , 3/23/2021



Organ Transplant Patients Responded Poorly to Single Dose of mRNA Vaccine

March 15, 2021

JAMA
The Journal of the
American Medical Association

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

BJ Boyarsky, JM Garonzik-Wang et al.

- Only 17% of participants mounted appreciable anti-spike antibody response (total n = 436)
- Full vaccination important for this population



Wild Card: SARS-CoV-2 Variants

B.1.1.7

originally United Kingdom

- **Covered well** by currently authorized mRNA vaccines; **likely covered** by J&J vaccine but more data needed

B.1.351

originally South Africa

- **Moderately to severely reduced** vaccine efficacy for some vaccines -- J&J 64% efficacy; Novavax 60% efficacy; AstraZeneca 10% efficacy vs. mild/moderate disease; Pfizer 100% efficacy (small numbers)

P.1

originally Brazil

- **Vaccine efficacy unknown (no clinical trials)**
- ***In vitro*** -- minimal/moderate loss of neutralizing activity by vaccine-induced antibodies

B.1.429/B.1.427

originally California

- **Vaccines are likely still effective**
- ***In vitro*** -- moderate loss of neutralizing activity by vaccine-induced antibodies

B.1.526

originally New York

- **Vaccine efficacy unknown**
- ***In vitro*** -- variable loss of neutralizing activity by vaccine-induced antibodies





THE WHITE HOUSE
WASHINGTON

WH.GOV